Comparison of Thermo-plastic Versus Carbon Foot Ankle Orthosis to Improve Gait and Reduce Fatigue in Post-stroke Patients: a Biomechanical and Neurophysiological Study
MECASPRY
2 other identifiers
interventional
15
1 country
1
Brief Summary
Approximately 20% of stroke survivors have difficulties to dorsiflex the ankle and clear the ground during walking. This impairment, termed as "foot drop", is caused by an association of weak dorsiflexors and increased spasticity and stiffness of the plantar-flexors. As a consequence, walking performances are reduced and energy cost of walking is deteriorated. This may increase performance fatigability, as the locomotion will be realized at a higher percentage of the subjects' capacities. In order to overcome these issues, different treatments are proposed. One of the most conventional solutions are the use of ankle foot orthosis (AFO) and it is the most commonly prescribed device used to compensate for "foot drop". There is a very large choice of AFO on the market which can be proposed to patients with foot drop. The aim of this study is thus to assess the mechanical effects of using a manufactured carbon AFO in by comparison to a custom-made thermo-plastic AFO on walking capacity (distance and energy cost), fatigue and "foot drop" control throughout the gait phase in patients with hemiparetic stroke.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Sep 2020
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 19, 2020
CompletedFirst Posted
Study publicly available on registry
March 27, 2020
CompletedStudy Start
First participant enrolled
September 7, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 23, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
November 23, 2021
CompletedJanuary 11, 2022
January 1, 2022
1.2 years
March 19, 2020
January 10, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Distance walked during the 6 Minute Walk Test (6MWT)
Patient will performed three experimental session (14 days between each session) during wich the primary outcome will be assessed : one session while walking with C-AFO, one session while walking with CM-AFO, and one session while walking without AFO (randomized order). 6 Minute Walk Test is a beneficial tool to evaluate walking endurance in patients with poststroke hemiparesis
Day : 14
Secondary Outcomes (7)
Energy cost
Day : 14
Muscular activity
Day: 14
Angle
Day : 14
Perceived fatigue
Day : 14
Power
Day : 14
- +2 more secondary outcomes
Study Arms (3)
Carbon-AFO (C-AFO)
EXPERIMENTALManufactured carbon ankle foot orthosis (C-AFO) Sprystep (Thuasne) will be provided to patients. A familiarization with C-AFO will be performed before doing the tests.
Custom-made thermo-plastic orthosis (CM-AFO)
ACTIVE COMPARATOROwn custom-made thermo-plastic orthosis (CM-AFO) of patients. A familiarization will be performed also before doing the tests.
Without orthosis (NO)
NO INTERVENTIONNo orthosis - patient will wear only their shoes
Interventions
The experimental protocol will require 4 visits: one inclusion visit and 3 visits for evaluations. Each visit corresponds to one condition: C-AFO, CM-AFO or NO (according to a random order). Visit #1 will consist in a clinical evaluation and a familiarization session with the measuring devices and methodologies used in visit#2 #3 and #4. During #2, #3 and #4 visits (14 days between each session), the subject will perform with C-AFO, CM-AFO or NO according to the random order : * 5 x 15m overground at a comfortable walking speed (CWS) where EMG, ground reaction force and kinematics will be measured * 6MWT where energy cost will be measured * 5 x 15m overground (immediately after the 6MWT) at a comfortable walking speed
Eligibility Criteria
You may qualify if:
- Hemiparetic patients, walking with CM-AFO
- Diagnosis of a first stroke since at least 6 months with medical conditions of stroke known, treatment proposed, cardio-vascular and neurological state stabilized
- Foot drop observed during the swing phase of gait, requiring the use of a custom-made plastic orthosis that has been used for at least 3 months and used for less than 2 years
- Muscle spasticity not higher than grade 3 according to the Modified Ashworth Scale
- Sufficient motor ability and endurance to ambulate at least 15 m independently without AFO
- Patient who signed a consent
- Patients affiliated or entitled to a social security system.
You may not qualify if:
- Patients who did not have brain MRI imaging after their stroke to confirm the diagnosis of stroke,
- Patients with an associated cerebellar syndrome,
- Patients with clinical brainstem involvement (cranial pair deficit),
- Patients with a neurological history other than stroke that has an impact on walking,
- Patients with unstable cardiovascular or respiratory disorders likely to induce gait disorders that may influence the performance of the tests to a greater extent than in the case of vascular hemiplegics,
- Patients with alcohol or drug dependence,
- Patients with psychiatric illness, cognitive impairment, uncontrolled disease/epilepsy, malignant pathology, renal impairment, unstable or decompensated diabetes, severe,
- Patients with a history of associated disabling systemic disease,
- Patients who refused to sign the written consent,
- Patients with a current pregnancy,
- Patients under court protection.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Thuasnelead
- University Hospital of Saint-Etiennecollaborator
Study Sites (1)
Chu Saint Etienne
Saint-Etienne, 42055, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Paul Calmels, MD,PhD
CHU Saint Etienne, Bellevue
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 19, 2020
First Posted
March 27, 2020
Study Start
September 7, 2020
Primary Completion
November 23, 2021
Study Completion
November 23, 2021
Last Updated
January 11, 2022
Record last verified: 2022-01